The $100 whole genome keeps coming up in lectures as the threshold where sequencing stops being a specialist tool and becomes a routine clinical one. But I wonder whether the bottleneck just shifts at that point. Most hospitals do not have the bioinformatics infrastructure to act on a whole genome meaningfully. Does cheaper sequencing accelerate that investment, or does it just create a larger backlog of data nobody knows what to do with?
The $100 whole genome keeps coming up in lectures as the threshold where sequencing stops being a specialist tool and becomes a routine clinical one. But I wonder whether the bottleneck just shifts at that point. Most hospitals do not have the bioinformatics infrastructure to act on a whole genome meaningfully. Does cheaper sequencing accelerate that investment, or does it just create a larger backlog of data nobody knows what to do with?
Thanks for the comment, this is spot on.